Application of Model for End-Stage Liver Disease score in end-stage liver disease

Rigan XIGU; Ya SU; Jing TONG; Bingyuan WANG

doi:10.12449/JCH250325

Volume 41 Issue 3

Mar. 2025

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(3): 556-560

PDF( 583 KB)

Application of Model for End-Stage Liver Disease score in end-stage liver disease

DOI: 10.12449/JCH250325

Rigan XIGU¹,
Ya SU^{1
,
,
,},
Jing TONG²,
Bingyuan WANG²

1.
Department of Gastroenterology，Affiliated Hospital of Inner Mongolia University for The Nationalities，Tongliao，Inner Mongolia 028000，China
2.
Department of Gastroenterology，The First Affiliated Hospital of China Medical University，Shenyang 110001，China

Research funding:

National Natural Science Foundation of China Young Scientist Fund (8170030364)

More Information

Corresponding author: SU Ya， suyajiayou2020@126.com （ORCID： 0009-0002-9193-3254）
Received Date: 2024-07-02
Accepted Date: 2024-08-15
Published Date: 2025-03-25

Abstract

Abstract

The Model for End-Stage Liver Disease （MELD） score is currently used to prioritize liver allocation for cirrhotic patients awaiting liver transplantation in the world. With the application of MELD score in transplantation for patients with severe conditions， several models have been proposed to refine and improve MELD score. MELD score has also been used for the management of non-transplantation patients with chronic liver disease. This article briefly reviews the background of these models and believes that the original intention of MELD is to determine the priority of organ allocation for liver transplantation. The expanded application of MELD score beyond liver transplantation assessment should be performed with reference to clinical practice， and different MELD models should be selected rationally based on individual conditions， in order to help patients achieve optimal prognosis assessment， intervention measures， and benefits.
- Liver Cirrhosis,
- Model for End-stage Liver Disease,
- Severity of Illness Index

FullText(HTML)

References(43)

References

[1]	SHARMA P, SCHAUBEL DE, SIMA CS, et al. Re-weighting the model for end-stage liver disease score components[J]. Gastroenterology, 2008, 135( 5): 1575- 1581. DOI: 10.1053/j.gastro.2008.08.004.
[2]	LEISE MD, KIM W RAY, KREMERS WK, et al. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation[J]. Gastroenterology, 2011, 140( 7): 1952- 1960. DOI: 10.1053/j.gastro.2011.02.017.
[3]	BIGGINS SW, RODRIGUEZ HJ, BACCHETTI P, et al. Serum sodium predicts mortality in patients listed for liver transplantation[J]. Hepatology, 2005, 41( 1): 32- 39. DOI: 10.1002/hep.20517.
[4]	KIM W RAY, MANNALITHARA A, HEIMBACH JK, et al. MELD 3.0: The model for end-stage liver disease updated for the modern era[J]. Gastroenterology, 2021, 161( 6): 1887- 1895. e 4. DOI: 10.1053/j.gastro.2021.08.050.
[5]	STARLINGER P, AHN JC, MULLAN A, et al. The addition of C-reactive protein and von willebrand factor to model for end-stage liver disease-sodium improves prediction of waitlist mortality[J]. Hepatology, 2021, 74( 3): 1533- 1545. DOI: 10.1002/hep.31838.
[6]	ASRANI SK, JENNINGS LW, KIM WR, et al. MELD-GRAIL-Na: Glomerular filtration rate and mortality on liver-transplant waiting list[J]. Hepatology, 2020, 71( 5): 1766- 1774. DOI: 10.1002/hep.30932.
[7]	GARBER K. Controversial allocation rules for liver transplants[J]. Nat Med, 2002, 8( 2): 97. DOI: 10.1038/nm0202-97a.
[8]	MALINCHOC M, KAMATH PS, GORDON FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology, 2000, 31( 4): 864- 871. DOI: 10.1053/he.2000.5852.
[9]	KAMATH PS, WIESNER RH, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33( 2): 464- 470. DOI: 10.1053/jhep.2001.22172.
[10]	WIESNER R, EDWARDS E, FREEMAN R, et al. Model for end-stage liver disease(MELD) and allocation of donor livers[J]. Gastroenterology, 2003, 124( 1): 91- 96. DOI: 10.1053/gast.2003.50016.
[11]	OLTHOFF KM, BROWN RS Jr, DELMONICO FL, et al. Summary report of a national conference: Evolving concepts in liver allocation in the MELD and PELD era. December 8, 2003, Washington, DC, USA[J]. Liver Transpl, 2004, 10(10 Suppl 2): A6- 22. DOI: 10.1002/lt.20247.
[12]	WIESNER R, LAKE JR, FREEMAN RB, et al. Model for end-stage liver disease(MELD) exception guidelines[J]. Liver Transpl, 2006, 12(12 Suppl 3): S85- S87. DOI: 10.1002/lt.20961.
[13]	LIM YS, LARSON TS, BENSON JT, et al. Serum sodium, renal function, and survival of patients with end-stage liver disease[J]. J Hepatol, 2010, 52( 4): 523- 528. DOI: 10.1016/j.jhep.2010.01.009.
[14]	ASRANI SK, KAMATH PS. Model for end-stage liver disease score and MELD exceptions: 15 years later[J]. Hepatol Int, 2015, 9( 3): 346- 354. DOI: 10.1007/s12072-015-9631-3.
[15]	QUANTE M, BENCKERT C, THELEN A, et al. Experience since MELD implementation: How does the new system deliver?[J]. Int J Hepatol, 2012, 2012: 264015. DOI: 10.1155/2012/264015.
[16]	D’AMICO G, GARCIA-TSAO G, PAGLIARO L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies[J]. J Hepatol, 2006, 44( 1): 217- 231. DOI: 10.1016/j.jhep.2005.10.013.
[17]	TEH SH, NAGORNEY DM, STEVENS SR, et al. Risk factors for mortality after surgery in patients with cirrhosis[J]. Gastroenterology, 2007, 132( 4): 1261- 1269. DOI: 10.1053/j.gastro.2007.01.040.
[18]	KAMATH PS, KIM W RAY, GROUP ALDS. The model for end-stage liver disease(MELD)[J]. Hepatology, 2007, 45( 3): 797- 805. DOI: 10.1002/hep.21563.
[19]	KREMERS WK, VAN IJPEREN M, KIM WR, et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients[J]. Hepatology, 2004, 39( 3): 764- 769. DOI: 10.1002/hep.20083.
[20]	KIM MS, KATO TS, FARR M, et al. Hepatic dysfunction in ambulatory patients with heart failure: Application of the MELD scoring system for outcome prediction[J]. J Am Coll Cardiol, 2013, 61( 22): 2253- 2261. DOI: 10.1016/j.jacc.2012.12.056.
[21]	MITRA A, MYERS L, AHN J. Assessing the severity and prognosis of alcoholic hepatitis[J]. Clin Liver Dis, 2021, 25( 3): 585- 593. DOI: 10.1016/j.cld.2021.03.004.
[22]	JOPHLIN LL, SINGAL AK, BATALLER R, et al. ACG clinical guideline: Alcohol-associated liver disease[J]. Am J Gastroenterol, 2024, 119( 1): 30- 54. DOI: 10.14309/ajg.0000000000002572.
[23]	FORREST EH, ATKINSON SR, RICHARDSON P, et al. Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis[J]. J Hepatol, 2018, 68( 3): 511- 518. DOI: 10.1016/j.jhep.2017.11.017.
[24]	MORALES-ARRÁEZ D, VENTURA-COTS M, ALTAMIRANO J, et al. The MELD score is superior to the maddrey discriminant function score to predict short-term mortality in alcohol-associated hepatitis: A global study[J]. Am J Gastroenterol, 2022, 117( 2): 301- 310. DOI: 10.14309/ajg.0000000000001596.
[25]	FINK MA, ANGUS PW, GOW PJ, et al. Liver transplant recipient selection: MELD vs. clinical judgment[J]. Liver Transpl, 2005, 11( 6): 621- 626. DOI: 10.1002/lt.20428.
[26]	HEUMAN DM, ABOU-ASSI SG, HABIB A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death[J]. Hepatology, 2004, 40( 4): 802- 810. DOI: 10.1002/hep.20405.
[27]	BIGGINS SW, KIM W RAY, TERRAULT NA, et al. Evidence-based incorporation of serum sodium concentration into MELD[J]. Gastroenterology, 2006, 130( 6): 1652- 1660. DOI: 10.1053/j.gastro.2006.02.010.
[28]	KALRA A, WEDD JP, BIGGINS SW. Changing prioritization for transplantation: MELD-Na, hepatocellular carcinoma exceptions, and more[J]. Curr Opin Organ Transplant, 2016, 21( 2): 120- 126. DOI: 10.1097/MOT.0000000000000281.
[29]	SHARMA P, SCHAUBEL DE, GOODRICH NP, et al. Serum sodium and survival benefit of liver transplantation[J]. Liver Transpl, 2015, 21( 3): 308- 313. DOI: 10.1002/lt.24063.
[30]	KIM JJ, KIM JH, KOO JK, et al. The Refit model for end-stage liver disease-Na is not a better predictor of mortality than the Refit model for end-stage liver disease in patients with cirrhosis and ascites[J]. Clin Mol Hepatol, 2014, 20( 1): 47- 55. DOI: 10.3350/cmh.2014.20.1.47.
[31]	CHETWOOD JD, WELLS MG, TSOUTSMAN T, et al. MELD-GRAIL and MELD-GRAIL-Na are not superior to MELD or MELD-Na in predicting liver transplant waiting list mortality at a single-center level[J]. Transplant Direct, 2022, 8( 7): e1346. DOI: 10.1097/TXD.0000000000001346.
[32]	THABUT D, MASSARD J, GANGLOFF A, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure[J]. Hepatology, 2007, 46( 6): 1872- 1882. DOI: 10.1002/hep.21920.
[33]	CAZZANIGA M, DIONIGI E, GOBBO G, et al. The systemic inflammatory response syndrome in cirrhotic patients: Relationship with their in-hospital outcome[J]. J Hepatol, 2009, 51( 3): 475- 482. DOI: 10.1016/j.jhep.2009.04.017.
[34]	BLAYA D, RUBIO-TOMÁS T, RODRIGO-TORRES D, et al. Endothelial dysfunction markers predict short-term mortality in patients with severe alcoholic hepatitis[J]. Hepatol Int, 2021, 15( 4): 1006- 1017. DOI: 10.1007/s12072-021-10165-y.
[35]	WOOD NL, VANDERWERKEN D, SEGEV DL, et al. Correcting the sex disparity in MELD-Na[J]. Am J Transplant, 2021, 21( 10): 3296- 3304. DOI: 10.1111/ajt.16731.
[36]	LOCKE JE, SHELTON BA, OLTHOFF KM, et al. Quantifying sex-based disparities in liver allocation[J]. JAMA Surg, 2020, 155( 7): e201129. DOI: 10.1001/jamasurg.2020.1129.
[37]	European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69( 2): 406- 460. DOI: 10.1016/j.jhep.2018.03.024.
[38]	KIM W RAY, MANNALITHARA A, KWO PY, et al. Mortality in patients with end-stage liver disease above model for end-stage liver disease 3.0 of 40[J]. Hepatology, 2023, 77( 3): 851- 861. DOI: 10.1002/hep.32770.
[39]	SINGEAP AM, MINEA H, PETREA O, et al. Real-world utilization of corticosteroids in severe alcoholic hepatitis: Eligibility, response, and outcomes[J]. Medicina(Kaunas), 2024, 60( 2): 311. DOI: 10.3390/medicina60020311.
[40]	KWONG AJ, EBEL NH, KIM WR, et al. OPTN/SRTR 2020 annual data report: Liver[J]. Am J Transplant, 2022, 22( Suppl 2): 204- 309. DOI: 10.1111/ajt.16978.
[41]	MAZUMDER NR, FONTANA RJ. MELD 3.0 in advanced chronic liver disease[J]. Annu Rev Med, 2024, 75: 233- 245. DOI: 10.1146/annurev-med-051322-122539.
[42]	PAPASTERGIOU V, TSOCHATZIS EA, PIERI G, et al. Nine scoring models for short-term mortality in alcoholic hepatitis: Cross-validation in a biopsy-proven cohort[J]. Aliment Pharmacol Ther, 2014, 39( 7): 721- 732. DOI: 10.1111/apt.12654.
[43]	LA DÍAZ, FUENTES-LÓPEZ E, AYARES G, et al. MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis[J]. JHEP Rep, 2023, 5( 8): 100727. DOI: 10.1016/j.jhepr.2023.100727.

Relative Articles

[1]	Yuanzhen WANG, Yaling YUN, Juan XIE, Liya HUANG. Value of five scoring systems in predicting the severity of hyperlipidemic acute pancreatitis: A comparative analysis[J]. Journal of Clinical Hepatology, 2023, 39(6): 1391-1397. doi: 10.3969/j.issn.1001-5256.2023.06.020
[2]	Yan WANG, Ying XU, Wei SUN, Li CHEN, Jianhe GAN, Jing GU. Value of interleukin-6 combined with Model for End-Stage Liver Disease score in predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(8): 1774-1779. doi: 10.3969/j.issn.1001-5256.2022.08.011
[3]	Shaoyu DONG, Changyu SUN, Fangfang QIAO, Xiao LIU, Jianying ZHANG. Value of age and D-dimer combined with Model for End-Stage Liver Disease in predicting the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(11): 2478-2482. doi: 10.3969/j.issn.1001-5256.2022.11.008
[4]	Qin ZHAO, Junjie YANG, Yanping ZHONG, Shan LI, Yuanyuan LIU, Xu LEI, Long LIU, Huabing TAN. Association between myostatin and sarcopenia in end-stage liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2692-2700. doi: 10.3969/j.issn.1001-5256.2021.11.045
[5]	Jin XU, Yan PENG, Chuankang TANG. Value of neutrophil-lymphocyte ratio combined with apolipoprotein A-I level in predicting the severity of acute pancreatitis in the early stage after admission[J]. Journal of Clinical Hepatology, 2021, 37(3): 660-665. doi: 10.3969/j.issn.1001-5256.2021.03.030
[6]	Nan GENG, Ming KONG, Yu CHEN, Zhongping DUAN. Value of L3 skeletal muscle index in nutritional diagnosis of end-stage liver disease[J]. Journal of Clinical Hepatology, 2021, 37(10): 2493-2496. doi: 10.3969/j.issn.1001-5256.2021.10.050
[7]	Jing GU, Yan WANG, Wei SUN, Weifeng ZHAO, Jianhe GAN. Value of interleukin-32 combined with Model for End-Stage Liver Disease in predicting the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(2): 304-308. doi: 10.3969/j.issn.1001-5256.2021.02.012
[8]	LIU ZhenLi, FAN ZuoPeng, LIU YaLi, ZHANG Jing. Value of Model for End-Stage Liver Disease and Child-Turcotte-Pugh score in predicting the prognosis of patients with hepatic sinus obstruction syndrome associated with Gynura segetum( Lour. ) Merr.[J]. Journal of Clinical Hepatology, 2020, 36(11): 2462-2466. doi: 10.3969/j.issn.1001-5256.2020.11.013
[9]	Gao Feng, Yan Zhen, Zhang Jie. Association between triglyceride level and the severity of acute hypertriglyceridemic pancreatitis[J]. Journal of Clinical Hepatology, 2018, 34(11): 2360-2363. doi: 10.3969/j.issn.1001-5256.2018.11.018
[10]	Wu YunZhong, Wang XianBo, Ye Hang, Jiang YuYong, Sun FengXia, Wang RongBing. The effecacy of Jieduliangxuefa for the patients with chronic severe hepatitis B: using model for end-stage liver diseases (MELD)[J]. Journal of Clinical Hepatology, 2011, 27(5): 467-470.
[11]	Han XueJing, Xiao Ye, Sun Min. Comparative study between the value of MESO index and MELD-Na in the short-term prognosis of decompensated liver cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(11): 1187-1189.
[12]	Wang XiaoRen, Yan BingZhu, Yang BaoShan. The prognostic assessment of model for end-stage liver disease (MELD) and total bile acids in patients with subacute liver failure[J]. Journal of Clinical Hepatology, 2011, 27(6): 638-640.
[13]	Chen LiHong, Hu NaiZhong, Wang YaLei. The value of MESO (MELD/Na index) scoring system in predicting prognosis of patients with cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1044-1046+1054.
[14]	Li JingYing, Lu LunGen. Progress of model for end-stage liver disease in the value of prognostic evaluation in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(7): 768-771+782.
[15]	Zheng XiaoLi, Wang LiangZhi, Wu BaoLi. Value of model for end-stage liver disease in prediction of prognosis in patients with decompensated hepatic cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(7): 738-740+745.
[16]	Zhan GuoQing, Tan HuaBing, Li Fang, Li RuGui, Zhang WeiWei, Li JinKe. Evaluation of model for end stage liver disease for estimation of short-term prognosis in decompensated cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(3): 280-282.
[17]	Liu ZhiHong, Jiang JianNing, Luo GuangHan, Wu JiZhou, Deng YiMing, Su MingHua, Wu JianLin, Zhang Lu. The value of MELD score for evaluation of plasma exchange in patients with liver failure[J]. Journal of Clinical Hepatology, 2010, 26(6): 615-617.
[18]	Zhan GuoQing, Zheng SanJu, Zhu Lin, Wang ChongHui, Li JinKe, Zhang WeiWei. The analysis of prognosis of patients with decompensated liver cirrhosis using the criterion of the model for end-stage liver disease and Child-Pugh grading[J]. Journal of Clinical Hepatology, 2009, 25(2): 114-116.
[19]	Zhan GuoQing, Zheng SanJu, Zhu Lin, Li JinKe. A retrospective analysis of prognosis on patients with severe hepatitis using the model for end-stage liver disease[J]. Journal of Clinical Hepatology, 2008, 24(2): 98-100.
[20]	Bai PingPing, Po YunFeng, Qin JunJie. The analysis of the short-term prognostic of cirrhotic patients using the criterion of model for end-stage liver disease and Child-Pugh grading[J]. Journal of Clinical Hepatology, 2007, 23(3): 193-194.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (118) PDF downloads(14)

Application of Model for End-Stage Liver Disease score in end-stage liver disease

DOI: 10.12449/JCH250325

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Application of Model for End-Stage Liver Disease score in end-stage liver disease

DOI: 10.12449/JCH250325

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content